

The Effect of Elution Volume for Immunoprecipitation on m⁶A-Seq Analysis

Yuhui Xu¹, Lize Shen², Guolin Li^{1*}

¹College of Life Sciences, Hunan Normal University, Changsha 410081, Hunan Province, China

²R&D Department, LC-Bio Technology Co., Ltd, Hangzhou 310018, Zhejiang Province, China

*Corresponding author: Guolin Li, hnsdlgl@hunnu.edu.cn

Abstract: Objective: To develop a cost-effective method to reduce the time consumption of elution in immunoprecipitation. **Method:** Two volumes (125 μ L for Group C and 100 μ L for Group T) of elution buffer were used to explore whether smaller volume could save testing time. **Result:** Time consumption of elution in Group T was significantly shorter than that in Group C, while the efficiency of eluted m⁶A-containing fragments and the performance of m⁶A-Seq as indicated by m⁶A peak distributions showed no difference between the two groups. **Conclusion:** A smaller volume of elution buffer was an economical way to reduce time consumption in immunoprecipitation.

Keywords: m⁶A-Seq; Immunoprecipitation; Elution buffer

Publication date: July 2021; **Online publication:** July 30, 2021

1. Introduction

Many studies have shown that N⁶-methyladenosine (m⁶A) RNA modification plays a key role in biological process, especially in the initiation and progression of different types of human cancers ^[1]. In 2012, the m⁶A landscape in humans and mice at whole transcriptional level was revealed by an immunoprecipitation-based next generation sequencing method called m⁶A-Seq (also known as MeRIP-Seq) ^[2-3]. However, m⁶A-Seq were still limited by time consumption of immunoprecipitation, higher amount of total RNA input for immunoprecipitation, bacterial contamination, etc. In this study, we reduced the elution volume of buffer in order to develop a more cost-effective method for immunoprecipitation and reduce time consumption during the whole experiment cycle.

2. Materials and methods

2.1. Cell line

The Mouse Renal Carcinoma cells (RenCa) were cultured in DMEM medium (Invitrogen) containing 10% FBS, 2 mM L-Glutamine and 1% penicillin-streptomycin. RenCa cell line was purchased from Allcells Biotechnology (Shanghai, China) and were routinely tested for mycoplasma contamination.

2.2. Equipment

| Equipment/resource | Source | Identifier |
|-----------------------------|----------------|------------|
| Water bath | Shanghai Boxun | DK-8D |
| Room temperature centrifuge | Eppendorf | 5415D |
| Refrigerated centrifuge | Eppendorf | 5418R |

(Continued next page)

(Continued)

| Equipment/resource | Source | Identifier |
|--------------------|---------------|------------|
| Vertical mixer | Ningbo Xinzhi | HS-3 |
| NanoDrop ND-1000 | NanoDrop | ND-1000 |
| Bioanalyzer 2100 | Agilent | G2939BA |
| Pipettor | Eppendorf | L17490H |

2.3. Reagent and buffer

| Reagent/resource | Source | Identifier | Storage (°C) |
|---------------------------------------|--------------------------|------------|--------------|
| TRIzol | Invitrogen | 15596026 | 2-8°C |
| Dynabeads® Oligo (dT) | Thermo Fisher | 25-61005 | 2-8°C |
| m ⁶ A antibody | Synaptic Systems (SYSY) | 202003 | -20°C |
| Magnesium RNA Fragmentation Module | New England Biolabs, Inc | E6150S | -20°C |
| Dynabeads Antibody Coupling Kit | Thermo Fisher | 14311D | 2-8°C |
| SuperScript™ II Reverse Transcriptase | Invitrogen | 1896649 | -20°C |
| <i>E. coli</i> DNA polymerase I | New England Biolabs, Inc | m0209 | -20°C |
| RNase H | New England Biolabs, Inc | m0297 | -20°C |
| dUTP Solution | Thermo Fisher | R0133 | -20°C |
| UDG enzyme | New England Biolabs, Inc | m0280 | -20°C |
| Truseq stranded mRNA library prep kit | Illumina | 15031047 | -20°C |

| Buffer | Components |
|---------------------------------|--|
| Fragment buffer | 10 mM ZnCl ₂ , 10 mM Tris-HCl (pH7.0) |
| Fragment stop buffer | 0.5 M EDTA |
| m ⁶ A binding buffer | 50 mM Tris-HCl (pH7.4), 150 mM NaCl, 1% NP-40, 2 mM EDTA |
| Low salt buffer | 0.2×SSPE, 0.001 M EDTA, 0.05% Tween-20 |
| High salt buffer | 0.2×SSPE, 0.001 M EDTA, 0.05%, Tween-20, 137.5 mM NaCl |
| TET buffer | 10 mM Tris-HCl (pH8.0), 1 mM EDTA (pH8.0), 0.05% Tween-20 |
| Elution buffer | 0.02 M DTT, 0.150 M NaCl, 0.05 M Tris-HCl (pH7.5), 0.001 M EDTA, 0.10% SDS |

2.4. RNA extraction and mRNA enrichment

Total RNA of cell line was isolated and purified using TRIzol reagent (Invitrogen, CA, USA) following the manufacturer's procedure. More than 300 µg total RNA was yielded by RenCa cell (3×10^8) in each sample. The RNA amount and purity were quantified using NanoDrop ND-1000 (NanoDrop, Wilmington, DE, USA). The RNA integrity was assessed by Bioanalyzer 2100 (Agilent, CA, USA) with RNA integrity number (RIN) >7.0 and confirmed by electrophoresis with denaturing agarose gel. Poly(A) RNA was purified from 300 µg total RNA using Dynabeads Oligo (dT) 25-61005 (Thermo Fisher, CA, USA) in four rounds of purification. Then, the poly(A) RNA was fragmented into small pieces using Magnesium RNA Fragmentation Module (NEB, cat.e6150, USA) under 86°C for 7 min. Amount of fragmented Poly(A) enriched RNA was 3458.4 ng and we equally separated into six tubes named with C1, C2, C3, T1, T2, and T3.

2.5. Immunoprecipitation

500 ng of poly(A) RNA was used for m⁶A-Seq in each biological replicate. 140 µL of pre-equilibrated m⁶A-Dynabeads was added to the 360 µL of fragmented RNA to a final volume of 500 µL. The fragmented

RNA was allowed to bind the m⁶A-Dynabeads at room temperature for 1 h. The tubes containing the samples were placed on a magnet allowing the bead complexes to cluster until the solution became clear. The liquid phase or supernatant in this 500 µL was discarded as this fraction represented the m⁶A negative fragments, which was not captured by the antibody. The m⁶A-Dynabeads-RNA complexes were resuspended and incubated in 500 µL of m⁶A Binding Buffer for 3 min at room temperature, and clear supernatant was removed after placing the beads in the magnet. Finally, high salt buffer, low salt buffer and TET buffer were added subsequently.

For immunoprecipitation, each biological replicate in Group T (T1, T2, T3) was treated with 100 µL elution buffer, while each biological replicate in Group C (C1, C2, C3) was treated with 125 µL elution buffer.

2.6. Library construction and sequencing

The eluted m⁶A-containing fragments (IP) and untreated input control fragments were reverse-transcribed to create cDNA libraries by SuperScript™ II Reverse Transcriptase (Invitrogen, cat. 1896649, USA), which were then used to synthesize U-labeled second-stranded DNAs with *E. coli* DNA polymerase I (NEB, cat.m0209, USA), RNase H (NEB, cat.m0297, USA) and dUTP Solution (Thermo Fisher, cat.R0133, USA). An A-base was then added to the blunt ends of each strand, preparing them for ligation to the indexed adapters. Each adapter contained a T-base overhang for ligating the adapter to the A-tailed fragmented DNA. Single- or dual-index adapters were ligated to the fragments, and size selection was performed using AMPureXP beads. After the heat-labile UDG enzyme (NEB, cat.m0280, USA) treatment of the U-labeled second-stranded DNAs, the ligated products were amplified with PCR by the following conditions: initial denaturation at 95°C for 3 min, 8 cycles of denaturation at 98°C for 15 sec, annealing at 60°C for 15 sec, extension at 72°C for 30 sec, and final extension at 72°C for 5 min. The average insert size for the final cDNA library was 300±50 bp. At last, 2×150bp paired-end sequencing (PE150) was performed on an Illumina Novaseq™ 6000 (LC-Bio Technology Co., Ltd., Hangzhou, China) following the manufacturer's recommended protocol.

2.7. Bioinformatic analysis of m⁶A-Seq

The fastp software (<https://github.com/OpenGene/fastp>) were used to remove the reads containing adaptor contamination, low quality bases and undetermined bases with default parameters. Then sequence quality of IP and Input samples were also verified using fastp. We used HISAT2 (<http://daehwankimlab.github.io/hisat2>) to map reads to the reference genome of *Mus musculus* (Ensembl Version: v96). The mapped reads of IP and input libraries were loaded into R package exomePeak (<https://bioconductor.org/packages/exomePeak>), which could identify m⁶A peaks with bed or bigwig format that could be adapted for visualization on the IGV software (<http://www.igv.org>). Called peaks were annotated by intersection with gene architecture using R package ChIPseeker (<https://bioconductor.org/packages/ChIPseeker>).

2.8. Statistical methods

Student's *t* test (*t.test* function) was utilized for data processing. The *P* value less than 0.01 (*P* < 0.01) was considered statistically significant.

3. Result

3.1. Less elution volume saves elution time

The IP efficiency of m⁶A modified RNA eluted by Group T (6.267%±0.64) and Group C (5.923%±1.07) was not significant difference (*P* > 0.1) (**Figure 1A**). However, the time consumption of elution in Group

T (109.67 ± 3.05 min) was significantly shorter ($P < 0.001$) than that in Group C (194 ± 8.89 min) (**Figure 1B**).




Figure 1. Less elution volume saves elution time. The immunoprecipitation (IP) efficiency (A) and time consumption (B) of elution in Group C (n=3) and Group T (n=3). Data were presented as mean \pm SEM, and ** represented $P < 0.001$ based on student's t test.

3.2. Less elution volume does not affect the distribution of m⁶A peaks in m⁶A-Seq

We next characterized the distribution of m⁶A peaks in the whole transcriptome of all samples. The metagenomic profiles of m⁶A peaks in both Group C and Group T indicated that m⁶A modifications were highly enriched around the 5' stop codon untranslated region (UTR) and 3' UTR (**Figure 2A**).

To confirm the distribution of m⁶A within the transcript, we divided the transcript into four non-overlapping segments: 5' UTR, 3' UTR, the first Exon and other Exons. Each m⁶A peak was assigned into one of the four transcript segments. The 3' UTR appeared to be greatly enriched in m⁶A peaks, and 49.82% to 50.13% of the peaks from the two groups fell into this segment (**Figure 2B**).




Figure 2. Lower elution volume does not affect the distribution of m⁶A peaks in m⁶A-Seq. Epi-Transcriptome analysis of total m⁶A peaks in Group C (n=3) and Group T (n=3). (A) Metagenomic profiles of m⁶A peak summit distributions along the transcripts composed of 5' UTR, CDS, and 3' UTR. (B) Pie charts depicting the distribution of m⁶A peak within four non-overlapping gene regions (5' UTR, 3' UTR, first exon, other exons).

These results were consistent with the m⁶A distribution in previous studies of m⁶A modification landscape in human and mouse [2-3], suggesting that the modified IP assay and library construction were successful.

4. Discussion

A classic protocol for m⁶A-Seq [2-3] included RNA extraction, poly(A) RNA enrichment, RNA binding to m⁶A-Dynabeads, washing of m⁶A-Dynabeads, elution of m⁶A-positive RNA, library construction, and Illumina sequencing. These steps may account for more than 36 hours, of which more than 2 hours will be spent on the elution step. The content of eluted m⁶A-containing fragments for library construction is no more than 50 ng. On the basis of canonical method for m⁶A immunoprecipitation, we reduced elution volume buffer from 125 μ L to 100 μ L. Lower volume of elution buffer could save almost 100 min than higher volume, but the performance of m⁶A-Seq proved that m⁶A peaks distributed on gene regions had no difference between the two conditions. In conclusion, 100 μ L elution buffer could save almost half of the working time in IP elution than the step using 125 μ L while maintaining similar performance in m⁶A-Seq.

Acknowledgments

We thank Mr Jinlong Kuang in LC-Bio Technology for his help with the sample collection process.

Disclosure statement

The authors declare no conflict of interest.

Author contributions

Yuhui Xu, Lize Shen, Guolin Li designed the experiments, performed all the experiments, and wrote the manuscript. Lize Shen designed and performed the bioinformatics analysis. All the authors commented and approved the paper.

References

- [1] Jiang XL, Liu BY, Nie Z, et al., 2021, The Role of m⁶A Modification in the Biological Functions and Diseases. *Signal Transduction and Targeted Therapy*, 6(1): 74.
- [2] Meyer KD, Saletore Y, Zumbo P, et al., 2012, Comprehensive Analysis of MRNA Methylation Reveals Enrichment in 3' UTRS and Near Stop Codons. *Cell*, 149(7): 1635-1646.
- [3] Dominissini D, Moshkovitz S, Schwartz, et al., 2012, Topology of the Human and Mouse m⁶a RNA Methylomes Revealed by m⁶a-Seq. *Nature*, 485(7397): 201-206.